Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Phase I Efficacy On Vascular Permeability In Patients With Advanced Colorectal Cancer

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00496509
First received: July 3, 2007
Last updated: January 24, 2011
Last verified: January 2011

July 3, 2007
January 24, 2011
August 2006
Not Provided
Assess by dynamic contrast-enhanced magnetic resonance imaging the effect of once daily dosing with ZD6474 on tumour perfusion and vascular permeability in patients with advanced colorectal cancer and liver metastases.
Same as current
Complete list of historical versions of study NCT00496509 on ClinicalTrials.gov Archive Site
  • Assessment of appropriate Pharmacokinetic parameters [ Time Frame: Predetermined timepoints after dose administration ]
  • Determine the population PK of ZD6474 and assess the relationship between both free and total plasma PK and measures of Pharmacological activity [ Time Frame: Predetermined timepoints after dose administration ]
  • Assessment of the effectiveness of ZD6474 as measured by objective response rate and progression free survival based on RECIST.
Same as current
Not Provided
Not Provided
 
Phase I Efficacy On Vascular Permeability In Patients With Advanced Colorectal Cancer
A Phase I, Open-Label Study To Assess The Effect of ZD6474 (ZACTIMA) On Vascular Permeability In Patients With Advanced Colorectal Cancer and Liver Metastases

A Phase I, Open-Label Study To Assess The Effect of ZD6474 (ZACTIMA) On Vascular Permeability In Patients with Advanced Colorectal Cancer and Liver Metastases.

Not Provided
Interventional
Phase 1
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Hepatocellular Carcinoma
  • Drug: ZD6474 (Zactima)
  • Procedure: Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MR)
  • Procedure: Biomarker Draws
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
24
October 2007
Not Provided

Inclusion Criteria:

  • Histologically confirmed metastatic colorectal adenocarcinoma (stage IV) with at least 1 measurable hepatic lesion of 20 mm or more on MRI and for whom no standard therapy is available.
  • WHO Performance status 0 - 2.
  • Life expectancy of at least 12 weeks

Exclusion Criteria:

  • Brain metastases or spinal cord compression, unless treated at least 4 weeks before entry and stable without steroid treatment for 10 days or greater.
  • Last dose of prior chemotherapy must be discontinued at least 4 weeks before the start of study treatment.
  • Last dose of radiotherapy received within 4 weeks before the start of study treatment excluding palliative radiotherapy.
  • Prior treatment with VEGFR TKIs
  • Serum bilirubin . 1.5 x the upper limit of reference range.
  • Serum creatinine >1.5 x ULRR or Creatinine clearance (as determined by the Cockcroft - Gault method) less than or equal to 50 mL/min.
  • ALT or AST >5 x ULRR
  • ALP >5 x ULRR
  • Evidence of severe or uncontrolled systemic disease or any concurrent conditions which in the investigators opinion make it undesirable for the patient to participate in the study or would jeopardize compliance with the protocol.
  • Any unresolved toxicity greater than CTCAE Grade 2 for previous anti-cancer therapy.
  • Significant cardiovascular event within 3 months before entry, or presence of cardiac disease that in the opinion of the investigator increases the risk of ventricular arrhythmia.
  • History of arrhythmia which is symptomatic or requires treatment (CTCAE grade 3) or asymptomatic sustained ventricular tachycardia. Atrial fibrillation, controlled by medication is not excluded.
  • Congenital long QT syndrome or 1st degree relative with sudden unexplained death under of 40 years of age.
  • Presence of Left Bundle Branch Block.
  • QTc with Bazett's correction unmeasurable or greater than or equal to 480 msec or greater of screening ECG.
  • Potassium <4.0 mmol/L despite supplementation, serum calcium (ionized or adjusted for albumin), or magnesium out of normal range despite supplementation.
  • Women who are pregnant or breast feeding.
  • Any concomitant medications that may cause QTc prolongation or induce or induce Torsades de Pointes or induce CTP3A4 function.
  • Hypotension not controlled by medical therapy.
  • Participation in a clinical study of any investigational pharmaceutical agent within 30 days prior to commencing study treatment.
  • Major surgery within 4 weeks or incompletely healed surgical incision.
  • Previous or current malignancies of other histologies within the last 5 years, with the exception of in situ carcinoma of the cervix and adequately treated basal cell or Squamous cell carcinoma of the skin.
  • Any contraindications to MRI scans.
  • Involvement in the planning or conduct of the study.
  • Previous enrollment or randomization of treatment in the present study.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
NCT00496509
D4200C00050
No
Not Provided
AstraZeneca
Not Provided
Principal Investigator: Klaus Mross, MD Albert-Ludwigs-Universitat
AstraZeneca
January 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP